EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Amyloid-beta (1–40) as an Emerging Biomarker for the Cardiovascular–Kidney–Metabolic Syndrome

Kimon Stamatelopoulos

Journal of Atherosclerosis Prevention and Treatment · 2026-01 · 17 (1) · 10-12

DOI: 10.4103/aptj.aptj_30_26 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Atherosclerosis Prevention and Treatment, online erschienen am 13.07.2026. Verfasst von Kimon Stamatelopoulos. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Amyloid-beta (Aβ) peptides are being increasingly recognized as key players in extracerebral pathophysiological processes beyond their established role in neurodegenerative diseases. Converging translational and epidemiological evidence points to a pivotal role of circulating Aβ1-40 across the full spectrum of cardiovascular–kidney–metabolic (CKM) syndrome. In clinical studies, elevated Αβ40 levels associate with systemic metabolic dysfunction, renal impairment, subclinical myocardial stress, arterial aging, and atherosclerotic plaque instability. Furthermore, Αβ40 independently predicts cardiovascular mortality, major adverse cardiac events, and heart failure hospitalizations in special cardiovascular populations. Standard-of-care cardiovascular therapies exert off-target effects on Aβ metabolism, while drugs targeting Αβ metabolism to treat Alzheimer’s disease have not been assessed for possible benefit in CKM. This commentary focuses on clinical data supporting the role of Aβ40 in CKM and discusses gaps in evidence that merit further investigation to validate its applicability as a possible prognostic biomarker and therapeutic target in this setting.

Zitieren

APA

Stamatelopoulos, K. (2026). Amyloid-beta (1–40) as an Emerging Biomarker for the Cardiovascular–Kidney–Metabolic Syndrome. Journal of Atherosclerosis Prevention and Treatment, 17(1), 10-12. https://doi.org/10.4103/aptj.aptj_30_26

Vancouver

Stamatelopoulos K. Amyloid-beta (1–40) as an Emerging Biomarker for the Cardiovascular–Kidney–Metabolic Syndrome. Journal of Atherosclerosis Prevention and Treatment. 2026;17(1):10-12. doi:10.4103/aptj.aptj_30_26

BibTeX
@article{Stamatelopoulos2026,
  author = {Stamatelopoulos, Kimon},
  title = {Amyloid-beta (1–40) as an Emerging Biomarker for the Cardiovascular–Kidney–Metabolic Syndrome},
  journal = {Journal of Atherosclerosis Prevention and Treatment},
  year = {2026},
  volume = {17},
  number = {1},
  pages = {10--12},
  doi = {10.4103/aptj.aptj_30_26}
}
Kostenlos starten →